|
1
|
Wei X, Dai J, Liu R, Wan G, Gu S, Du Y, Yang X, Wang L, Huang Y, Chen P, Chen X, Yang X, Wang Q. S/O/W Emulsion with CAPE Ameliorates DSS-Induced Colitis by Regulating NF-κB Pathway, Gut Microbiota and Fecal Metabolome in C57BL/6 Mice. Nutrients 2024; 16:1145. [PMID: 38674835 PMCID: PMC11054280 DOI: 10.3390/nu16081145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 04/09/2024] [Accepted: 04/10/2024] [Indexed: 04/28/2024] Open
Abstract
Inflammatory bowel disease (IBD) has attracted much attention worldwide due to its prevalence. In this study, the effect of a solid-in-oil-in-water (S/O/W) emulsion with Caffeic acid phenethyl ester (CAPE, a polyphenolic active ingredient in propolis) on dextran sulfate sodium (DSS)-induced colitis in C57BL/6 mice was evaluated. The results showed that CAPE-emulsion could significantly alleviate DSS-induced colitis through its effects on colon length, reduction in the disease activity index (DAI), and colon histopathology. The results of ELISA and Western blot analysis showed that CAPE-emulsion can down-regulate the excessive inflammatory cytokines in colon tissue and inhibit the expression of p65 in the NF-κB pathway. Furthermore, CAPE-emulsion promoted short-chain fatty acids production in DSS-induced colitis mice. High-throughput sequencing results revealed that CAPE-emulsion regulates the imbalance of gut microbiota by enhancing diversity, restoring the abundance of beneficial bacteria (such as Odoribacter), and suppressing the abundance of harmful bacteria (such as Afipia, Sphingomonas). The results of fecal metabolome showed that CAPE-emulsion restored the DSS-induced metabolic disorder by affecting metabolic pathways related to inflammation and cholesterol metabolism. These research results provide a scientific basis for the use of CPAE-emulsions for the development of functional foods for treating IBD.
Collapse
Affiliation(s)
- Xuelin Wei
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Juan Dai
- School of Laboratory Medicine, Chengdu Medical College, Chengdu 610500, China;
| | - Ruijia Liu
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Guochao Wan
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Shiyu Gu
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Yuwei Du
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Xinyue Yang
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Lijun Wang
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Yukun Huang
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Pengfei Chen
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
| | - Xianggui Chen
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
- Chongqing Key Laboratory of Specialty Food Co-Built by Sichuan and Chongqing, Chengdu 610039, China
| | - Xiao Yang
- School of Food and Bioengineering, Xihua University, Chengdu 610039, China; (X.W.); (R.L.); (G.W.); (S.G.); (Y.D.); (X.Y.); (L.W.); (Y.H.); (P.C.); (X.C.)
- Chongqing Key Laboratory of Specialty Food Co-Built by Sichuan and Chongqing, Chengdu 610039, China
| | - Qin Wang
- Department of Nutrition and Food Science, University of Maryland, College Park, MD 20742, USA
| |
Collapse
|
|
2
|
Abstract
Cardiovascular diseases (CVDs) still remain the leading concern of global health, accounting for approximately 17.9 million deaths in 2016. The pathogenetic mechanisms of CVDs are multifactorial and incompletely understood. Recent evidence has shown that alterations in the gut microbiome and its associated metabolites may influence the pathogenesis and progression of CVDs such as atherosclerosis, heart failure, hypertension, and arrhythmia, yet the underlying links are not fully elucidated. Owing to the progress in next-generation sequencing techniques and computational strategies, researchers now are available to explore the emerging links to the genomes, transcriptomes, proteomes, and metabolomes in parallel meta-omics approaches, presenting a panoramic vista of culture-independent microbial investigation. This review aims to outline the characteristics of meta-omics pipelines and provide a brief overview of current applications in CVDs studies which can be practical for addressing crucial knowledge gaps in this field, as well as to shed its light on cardiovascular risk biomarkers and therapeutic intervention in the near future.
Collapse
Affiliation(s)
- Jing Xu
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital & National Center for Cardiovascular Diseases, Beijing, China,Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Yuejin Yang
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital & National Center for Cardiovascular Diseases, Beijing, China,Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China,CONTACT Yuejin Yang State Key Laboratory of Cardiovascular Disease, Fuwai Hospital & National Center for Cardiovascular Disease, Beijing, China; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| |
Collapse
|
|
3
|
The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients 2020; 12:nu12030605. [PMID: 32110880 PMCID: PMC7146472 DOI: 10.3390/nu12030605] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Revised: 02/19/2020] [Accepted: 02/21/2020] [Indexed: 12/23/2022] Open
Abstract
The importance of gut microbiota in health and disease is being highlighted by numerous research groups worldwide. Atherosclerosis, the leading cause of heart disease and stroke, is responsible for about 50% of all cardiovascular deaths. Recently, gut dysbiosis has been identified as a remarkable factor to be considered in the pathogenesis of cardiovascular diseases (CVDs). In this review, we briefly discuss how external factors such as dietary and physical activity habits influence host-microbiota and atherogenesis, the potential mechanisms of the influence of gut microbiota in host blood pressure and the alterations in the prevalence of those bacterial genera affecting vascular tone and the development of hypertension. We will also be examining the microbiota as a therapeutic target in the prevention of CVDs and the beneficial mechanisms of probiotic administration related to cardiovascular risks. All these new insights might lead to novel analysis and CVD therapeutics based on the microbiota.
Collapse
|